HEM Securities's research report on Unichem LabsUnichem Laboratories Ltd. is an international, integrated, specialty pharmaceutical company. It manufacturers and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, orthopedics and anti-infectives.With strong traction in the US markets, focus to entry in new geographies, increased business driven by volume growth and continued dominance of key products of Unichem depicts the growth path of the company in times ahead. We believe the company is trading at an attractive valuation at 18.67x and 14.87x of consolidated FY16EPS of Rs.11.71 and FY17EPS of Rs.14.71. We initiate a ‘BUY’ on the stock with a target price of Rs.290 (appreciation of about 33%) with the medium to long term investment horizon.For all recommendations, click here Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
